Price
Target price
€9.66
€9.66
-1.430%
-0.14
-1.430%
€25.90
12:26 / Tradegate
WKN: A2AG6H / Symbol: NTLA / Name: Intellia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Intellia Therapeutics Inc Stock
We can see a decrease in the price for Intellia Therapeutics Inc. Compared to yesterday it has lost -€0.140 (-1.430%).
Currently there is a rather positive sentiment for Intellia Therapeutics Inc with 22 Buy predictions and 7 Sell predictions.
With a target price of 25 € there is potential for a 158.75% increase which would mean more than doubling the current price of 9.66 € for Intellia Therapeutics Inc.
Our community identified positive and negative aspects for Intellia Therapeutics Inc stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Intellia Therapeutics Inc stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | -1.430% | 4.254% | -0.102% | 6.939% | 25.570% | -73.816% | -82.584% |
| Arbutus Biopharma Corp. | -4.900% | 8.997% | -12.215% | 6.332% | -15.454% | 34.924% | -4.959% |
| Compugen Ltd. | -1.270% | -6.736% | -15.394% | -31.265% | 9.422% | 84.615% | - |
| Protalix Biotherapeutics Inc. | 7.020% | -0.806% | 36.667% | -4.429% | 60.784% | 66.554% | -39.109% |
Comments
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
News
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?
Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes biotechs that specialize in gene editing, a group of techniques that could
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares
On Jan. 5, John M. Leonard, the president and CEO of Intellia Therapeutics (NASDAQ:NTLA), executed an open-market sale of 34,146 directly held shares, totaling $314,484.66, as disclosed in a SEC
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street
Intellia Therapeutics (NASDAQ: NTLA) and Iovance Biotherapeutics (NASDAQ: IOVA) are relatively innovative biotech companies. However, due to company-specific headwinds, both have seen their shares